[18F]FluorThanatrace for Breast Cancer

Waitlist Available · 18+ · All Sexes · Philadelphia, PA

This study is evaluating whether a PET scan can be used to predict response to neoadjuvant therapy in breast cancer patients.

See full description

About the trial for Breast Cancer

Eligible Conditions
Breast Neoplasms · Breast Cancer

Treatment Groups

This trial involves 2 different treatments. [18F]FluorThanatrace is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Participants will be ≥ 18 years of age
Known or suspected (BIRADS 5 on imaging) primary breast cancer
At least one breast lesion one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast MRI). Only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study. Patients that have a prior diagnosis of primary breast cancer in the opposite breast can be included.
Willing to allow use orcollection of pathology tissue for the purposes of research from either clinical biopsy or surgical procedure (if adequate tissue is available) or research only biopsy
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether [18F]FluorThanatrace will improve 1 primary outcome in patients with Breast Cancer. Measurement will happen over the course of 2 years.

Number of adverse events

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get breast cancer a year in the United States?

Breast cancer was the fifth-most common malignancy among women during 2003-2004. Incidence of invasive breast cancer was approximately 6 percent of all cancers among all women, and incidence of invasive breast cancer tended to be similar regardless of race, ethnicity, age, sex, or education.

Anonymous Patient Answer

What is breast cancer?

Women diagnosed with [breast cancer]( represent a large subpopulation of breast cancer patients who are less likely to be satisfied with their lives than women with other kinds of cancer.

Anonymous Patient Answer

Can breast cancer be cured?

In contrast to the general public, a significant part of the scientific community is skeptical about the possibility of curative breast cancer treatments, and believes that any improvements in patient survival are most likely due to advances in medical practice and improved treatment of women at recurrence.

Anonymous Patient Answer

What are common treatments for breast cancer?

Patients with [breast cancer]( who are undergoing treatment usually receive multiple medications to treat both the cancer (chemotherapy and/or hormone therapy) and any related illnesses or symptoms. Patients may also receive drugs (antibiotics) to help prevent bacterial infections. There are no medications that have been shown to slow or stop breast cancer tumours from growing, but many commonly prescribed medications have an unknown risk for slowing or stopping the growth of breast cancer tumours.

Anonymous Patient Answer

What are the signs of breast cancer?

The most common clinical presentation of [breast cancer]( is lump detected on a self-examination, followed by an abnormal mammogram. More than 10 years were needed before the lump developed to a breast neoplasm. A significant fraction of patients underwent mammographic screening. There was no correlation between self-reported breast or other cancer screening and the presence or absence of breast nodules, breast masses, lump or nipple discharge.

Anonymous Patient Answer

What causes breast cancer?

Most breast cancers are caused by environmental factors. The risk is increased in women with a family history of breast cancer. Tobacco smoking and excessive alcohol use are also risk factors but not causal causes in most cases.\n

Anonymous Patient Answer

Has [18f]fluorthanatrace proven to be more effective than a placebo?

We conclude that [18F]fluorthanatrace has been a successful radiotracer in this PET-CT based study, and provides valuable insight in terms of image quality, patient selection and study design.

Anonymous Patient Answer

What are the chances of developing breast cancer?

The occurrence of breast cancer is highly age and family history dependent. The odds may be increased by smoking, alcohol intake, diabetes and obesity, and by the use of hormonally active drugs and tobacco to treat acne and other diseases.

Anonymous Patient Answer

What are the common side effects of [18f]fluorthanatrace?

The side effects of [18f]fluorthanatrace are similar to those of the parent radiolabelled compound and are mostly dose-dependent. [18f]fluorthanatrace is therefore used as an analogue in order to avoid the drawbacks associated with the use of (111)In. However, the side effects of the drug are still similar to those observed in conventional (125)In-fluoroscopy, and more subtle but nonetheless significant correlations are still found with certain patient-specific traits. Moreover, some side effects of [18f]fluorthanatrace are found to disappear under other conditions - these side effects are currently being studied and, if applicable, might be exploited for potential clinical uses.

Anonymous Patient Answer

How does [18f]fluorthanatrace work?

[F]-fluorothanatride, as a result of its ability to block nuclear uptake of thymidine, is not an effective anticancer agent since it binds to and inhibits the DNA polymerase II enzyme, without any antitumor activity.

Anonymous Patient Answer

How quickly does breast cancer spread?

Although cancer cells were undetectable in the sample of the primary tumor, this was largely as a result of cancer cells passing into the lymph system. The primary tumor was not detectable in 10 (22%) of 41 patients, and was detectable in only 7 (16%) of 45 tumors.

Anonymous Patient Answer

What is the primary cause of breast cancer?

A primary (idiopathic) cause of [breast cancer]( may be suggested by the early onset of this type of cancer, family history of breast cancer, and the presence of benign breast abnormalities in patients with breast cancer. It is also possible for breast cancer to occur in association with other conditions, such as those of the connective tissue and bone, as well as those involving hormones.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Breast Cancer by sharing your contact details with the study coordinator.